- Home
- ORIC vs PHAT Comparison
ORIC vs PHAT Comparison
Compare ORIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.3M | 894.0M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ORIC | PHAT |
|---|---|---|
| Price | $8.20 | $12.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $19.73 | ★ $19.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.67 | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $4.65 | $3.69 |
| 52 Week High | $14.93 | $18.31 |
Technical Indicators
Market Signals| Indicator | ORIC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 31.58 | 48.15 |
| Support Level | $7.90 | $10.38 |
| Resistance Level | $13.89 | $12.52 |
| Average True Range (ATR) | 0.50 | 0.98 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 4.87 | 61.97 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.